Microbot Medical Inc. (MBOT): Price and Financial Metrics
MBOT Price/Volume Stats
Current price | $1.09 | 52-week high | $4.37 |
Prev. close | $1.11 | 52-week low | $1.00 |
Day low | $1.08 | Volume | 87,600 |
Day high | $1.17 | Avg. volume | 128,872 |
50-day MA | $1.28 | Dividend yield | N/A |
200-day MA | $1.73 | Market Cap | 12.76M |
MBOT Stock Price Chart Interactive Chart >
Microbot Medical Inc. (MBOT) Company Bio
Microbot Medical Inc. operates as a medical device company. The Company specializes in the research, design, development, and commercialization of micro-robotics assisted medical technologies. Microbot Medical offers its services in the United States.
Latest MBOT News From Around the Web
Below are the latest news stories about MICROBOT MEDICAL INC that investors may wish to consider to help them evaluate MBOT as an investment opportunity.
Microbot Medical Announced Positive Results of Its GLP Pivotal Pre-Clinical Study Where All Study Objectives Were MetThe results of the study will support the Company’s IDE submission to the FDA to commence its human clinical studyBRAINTREE, Mass., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic Surgical System, today announces the successful completion of its GLP pivotal pre-clinical study, done under the guidelines of FDA-required levels of planning, controlling, monitoring, and reporting, using a porcine model. As previously a |
Microbot Medical and Corewell Health Forge Collaboration to Establish the LIBERTY® Endovascular Robotic Surgical System for TeleroboticThe first phase in the collaboration will evaluate the current state of the LIBERTY® Robotic Surgical System in connection with remote enabled Endovascular treatmentsBRAINTREE, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic Surgical System, today announced it has entered into a collaboration agreement with Corewell Health™. The objective of the collaboration, which will take place in multiple phases, is to |
3 Stocks at the Forefront of Medical RoboticsEvery now and then, speculation – within carefully defined limits – may be appropriate, which brings us to the case for medical robotics stocks to buy. |
Microbot Medical Announces the Successful Completion of Its GLP Pivotal Pre-Clinical Study, a Critical Milestone for Its IDE submission to Commence Human Clinical StudyThe final histopathology and lab report supplements previous positive Company findings. The results of the study will support the Company’s IDE submission to the FDA to commence its human clinical study. BRAINTREE, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic Surgical System, today announces the successful completion of its GLP pivotal pre-clinical study, done under the guidelines of FDA-required levels o |
Microbot Medical Appoints Seasoned Medical Expert Dr. Juan Diaz- Cartelle as its New Chief Medical Officer in Anticipation of Its Clinical, Regulatory and Commercial ActivitiesThe former Senior Medical Director for the Peripheral Interventions Division at Boston Scientific Corporation joins the Company as it transitions to the clinical and regulatory phase.BRAINTREE, Mass., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic Surgical System, today announced the appointment of Dr. Juan Diaz-Cartelle as its new Chief Medical Officer (CMO), effective December 1, 2023. The hiring of Dr. Diaz-Car |
MBOT Price Returns
1-mo | -15.50% |
3-mo | -19.85% |
6-mo | -20.73% |
1-year | -51.56% |
3-year | -87.60% |
5-year | -86.38% |
YTD | -33.54% |
2023 | -45.51% |
2022 | -59.87% |
2021 | 8.85% |
2020 | -32.25% |
2019 | 491.28% |
Loading social stream, please wait...